Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Mouse model demonstrates cell-to-cell connections between implanted stem cells and diseased cells

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research), the Karolinska Institutet, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School and Universit- Libre de Bruxelles have demonstrated in mouse models that transplanted stems cells, when in direct contact with diseased neurons, send signals through specialized channels that rescue the neurons from death.

2 Feb 2010

GMC designated as NMDP collection site to collect bone marrow from willing donors

Geisinger Medical Center (GMC) was recently designated a National Marrow Donation Program (NMDP) collection site, becoming the only site in the region to collect bone marrow or blood stem cells from willing donors.

2 Feb 2010

New technology aims to restore lost bone and gum tissue following periodontal disease

Advances in tissue engineering are offering the promise of being able to restore lost bone and gum tissue following periodontal disease.

2 Feb 2010

Stem Cell Therapy International completes merger with Histostem of South Korea

Stem Cell Therapy International, Inc. announced that it has completed its merger with Histostem Ltd. of South Korea ("Histostem"), forming one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity.

2 Feb 2010

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Managing Myeloma (www.ManagingMyeloma.com) convened the 2010 Multidisciplinary Advisory Board on January 16, 2010 to review the past 18 months and discuss the educational and practical needs of myeloma practitioners in an evolving therapeutic landscape.

1 Feb 2010

Project A.L.S. and Robert Packard Center for ALS Research partner in $15M research initiative

Project A.L.S. (New York, NY) and the Robert Packard Center for ALS Research at Johns Hopkins University (Baltimore, MD) announced that they will partner on P2 ALS, a $15 million initiative designed to advance ALS (Lou Gehrig's disease) research exponentially over the next three years.

30 Jan 2010

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

Rubicon Genomics, Inc., a developer of pre-analytical amplification products that enable more comprehensive genetic analysis of clinical and research samples, announced today that it has reached agreement with ZyGEM to non-exclusively market Rubicon's PicoPlex™ single-cell amplification kits in Australia and New Zealand.

30 Jan 2010

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

The BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category goes in this second edition to Prof. Robert J. Lefkowitz (1943, New York, United States), investigator in the Department of Medicine at Duke University (United States).

29 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

New understanding of CD44 receptor's role in immune cell survival

Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a new way the cell surface protein, CD44, helps specific T helper (Th1) cells develop immunologic memory.

29 Jan 2010

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

In a major step toward commercialization of a promising therapeutic treatment, Oak Ridge National Laboratory contractor UT-Battelle announced at a signing ceremony here today that it has exclusively licensed patents on inventions based on the Nell-1 gene to NellOne Therapeutics, Inc. (NellOne), a company spun out of research performed at the Department of Energy laboratory.

29 Jan 2010

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

New research in the FASEB Journal shows that bone marrow cells fuse to different types of cells, including embryonic stem cells, creating new hybrids that may evade immune rejection

29 Jan 2010

iPierian receives UK patent for induced pluripotent stem cell technology

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that the Intellectual Property Office in the United Kingdom has issued a Notification of Grant to iPierian for UK patent No. GB2450603, its first patent related to induced pluripotent stem cell (iPSC) technology.

29 Jan 2010

NIDA supports Omeros' Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers.

28 Jan 2010

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Life Technologies Corporation today announced results for its fourth quarter and full year ending December 31, 2009. Non-GAAP revenue for the fourth quarter was $874 million, resulting in full year non-GAAP revenues of $3.30 billion, an increase of 5 percent over the $3.14 billion reported for 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

New technique could reduce animal use in gene study

A new method of priming early embryos to form embryonic stem (ES) cells has allowed ES cells to be derived from mice used in diabetes research for the first time.

28 Jan 2010

New insight into reprogramming of cells

A discovery by Babraham scientists brings new insight into how cells are reprogrammed and a greater understanding of how the environment, or factors like nutritional signals, can interact with our genes to affect health. As an embryo develops, cells acquire a particular fate, for example becoming a nerve or skin cell. The findings, reported online in the journal Nature, pinpoint a protein called AID as being important for complete cellular reprogramming in mammals.

28 Jan 2010

Scientists discover new technique to investigate cancer stem cells

Scientists at Oxford University, funded by Cancer Research UK, have discovered a way to investigate cancer stem cells more efficiently in the laboratory.

28 Jan 2010

Stem Cells News and Research

Further Reading

Mouse model demonstrates cell-to-cell connections between implanted stem cells and diseased cells

GMC designated as NMDP collection site to collect bone marrow from willing donors

New technology aims to restore lost bone and gum tissue following periodontal disease

Stem Cell Therapy International completes merger with Histostem of South Korea

Researchers design bioactive nanomaterial that promotes cartilage growth

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Project A.L.S. and Robert Packard Center for ALS Research partner in $15M research initiative

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

BBVA Foundation Frontiers of Knowledge Award granted to Robert J. Lefkowitz

Global market for oncology drugs is forecast to reach $80 billion by 2050

New understanding of CD44 receptor's role in immune cell survival

UT-Battelle exclusively licenses patents on inventions based on Nell-1 gene

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

iPierian receives UK patent for induced pluripotent stem cell technology

NIDA supports Omeros' Addiction program

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Celgene reports total revenue of $758M for fourth-quarter of 2009

New technique could reduce animal use in gene study

New insight into reprogramming of cells

Scientists discover new technique to investigate cancer stem cells

eBook: Integrated solutions for mesenchymal stem cell research and culture eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo